promis™ neurosciences, inc. (tse: pmn, https://ca.finance.yahoo.com/q/bc?s=pmn.to), is a development stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular alzheimer’s disease (ad) and amyotrophic lateral sclerosis (als). the company’s scientific foundation centers on the growing knowledge base relating to diseases characterized by the presence of abnormal, misfolded proteins. several neurodegenerative diseases exhibit protein misfolding, such as ad, als, and parkinson’s disease (pd). recent published evidence indicates that for a given misfolded protein there exist multiple prion-like strains, each strain representing a specific target against which specific therapeutics can be developed. the company is focused on the discovery and development of precision therapeutics and companion diagnostics to combat the several strains of beta-amyloid (aβ) and tau i
Company profile
Ticker
PMN
Exchange
Website
CEO
Elliot Goldstein
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMORFIX LIFE SCIENCES LTD
SEC CIK
Corporate docs
Subsidiaries
ProMIS Neurosciences (US), Inc. ...
PMN stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
8 Dec 23
8-K
Regulation FD Disclosure
20 Nov 23
8-K
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
EFFECT
Notice of effectiveness
2 Oct 23
EFFECT
Notice of effectiveness
2 Oct 23
S-3/A
Shelf registration (amended)
27 Sep 23
S-3/A
Shelf registration (amended)
27 Sep 23
CORRESP
Correspondence with SEC
27 Sep 23
CORRESP
Correspondence with SEC
27 Sep 23
Latest ownership filings
4
Gavin T. Malenfant
30 Oct 23
4
Johanne Kaplan
30 Oct 23
4
LARRY DOUGLAS ALTSTIEL
30 Oct 23
4
Max A. Milbury
30 Oct 23
4
Neil Cashman
30 Oct 23
4
Daniel E. Geffken
30 Oct 23
3
Jeremy M. Sclar
5 Sep 23
SC 13G/A
GORDON MICHAEL S
5 Sep 23
SC 13G/A
Sclar Jeremy M.
5 Sep 23
SC 13G
SPHERA FUNDS MANAGEMENT LTD.
30 Aug 23
Financial summary
| Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 16.87 mm | 16.87 mm | 16.87 mm | 16.87 mm | 16.87 mm | 16.87 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 839.18 k | 1.58 mm | (no burn) | 213.21 k |
| Cash used (since last report) | n/a | n/a | 1.95 mm | 3.65 mm | n/a | 494.38 k |
| Cash remaining | n/a | n/a | 14.92 mm | 13.21 mm | n/a | 16.37 mm |
| Runway (months of cash) | n/a | n/a | 17.8 | 8.4 | n/a | 76.8 |
Institutional ownership, Q3 2023
30.4% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 16 |
| Opened positions | 3 |
| Closed positions | 2 |
| Increased positions | 3 |
| Reduced positions | 5 |
| 13F shares | Current |
|---|---|
| Total value | 5.59 bn |
| Total shares | 5.74 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Sphera Funds Management | 1.83 mm | $3.69 bn |
| Gordon Michael S | 1.69 mm | $3.09 mm |
| Sclar Jeremy M. | 1.24 mm | $2.56 mm |
| Ally Bridge | 531.92 k | $1.05 bn |
| Affinity Asset Advisors | 265.96 k | $526.68 mm |
| Northeast Financial Consultants | 100.00 k | $198.03 mm |
| Ieq Capital | 39.19 k | $77.61 mm |
| Fiduciary Trust | 20.01 k | $39.62 mm |
| CLARET ASSET MANAGEMENT | 10.83 k | $22.00 k |
| BAC Bank Of America | 1.67 k | $3.30 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 26 Oct 23 | Geffken Daniel E. | Option Common Shares | Grant | Acquire A | No | No | 1.87 | 2,500 | 4.68 k | 2,500 |
| 26 Oct 23 | Neil Cashman | Option Common Shares | Grant | Acquire A | No | No | 1.87 | 12,500 | 23.38 k | 12,500 |
| 26 Oct 23 | Max A. Milbury | Option Common Shares | Grant | Acquire A | No | No | 1.87 | 12,500 | 23.38 k | 12,500 |
| 26 Oct 23 | Larry Douglas Altstiel | Option Common Stock | Grant | Acquire A | No | No | 1.87 | 12,500 | 23.38 k | 12,500 |
| 26 Oct 23 | Johanne Kaplan | Option Common Shares | Grant | Acquire A | No | No | 1.87 | 12,500 | 23.38 k | 12,500 |